EX-32.1 4 f10k2014ex32i_dandritbio.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION

In connection with the Annual Report of Dandrit Biotech USA, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), we, Eric Leire, Chief Executive Officer (Principal Executive Officer) and Robert Wolfe, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of our knowledge:

(1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: March 31, 2015 |
/s/ Eric Leire |
Eric Leire |
Chief Executive Officer (Principal Executive Officer) |
/s/ Robert Wolfe |
Robert Wolfe |
Chief Financial Officer (Principal Financial and Accounting Officer) |